as on November 21, 2025 at 9:38 pm IST
Day's Low
Day's High
1.03%
Downside
4.93%
Upside
52 Week's Low
52 Week's High
52.67%
Downside
399.20%
Upside
Check Moonlake Immunotherapeutics market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.
Market Cap
$921.0M
EPS (TTM)
-3.5832
Dividend Yield
0.00%
Quarterly Earnings Growth YOY
0.00%
PE Ratio (TTM)
0PEG Ratio
0EBITDA
-227.0M
Revenue (TTM)
-
Profit Margin
0.00%
Return On Equity TTM
-54.33%
Compare market cap, revenue, PE, and other key metrics of Moonlake Immunotherapeutics with its industry peers.
Company | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin % |
|---|---|---|---|---|---|
| BUY | $921.0M | NA | NA | 0.00% | |
| BUY | $42.6B | 410.98% | -16.34 | -264.83% | |
| BUY | $60.9B | 257.49% | 1439.88 | 1.36% | |
| BUY | $107.9B | 96.24% | 29.59 | 31.35% | |
| BUY | $74.5B | 42.08% | 16.84 | 32.13% |
The Moonlake Immunotherapeutics stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.
*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.
Investment Value
₹1,00,000
Moonlake Immunotherapeutics investment value today
Current value as on today
₹30,324
Returns
Returns from Moonlake Immunotherapeutics Stock
Dollar Returns*
₹6,085 (+6.09%)
Based on 22 analysts
81.82%
Buy
18.18%
Hold
0.00%
Sell
Based on 22 analysts, 81.82% of analysts recommend a 'BUY' rating for Moonlake Immunotherapeutics. Average target price of $14.89
Get share price movements and forecasts by analysts on Moonlake Immunotherapeutics.
What analysts predicted
15.58%UPSIDE
Target Price
$14.89
Current Price
$12.57
Analyzed by
22 Analysts
Target
$14.89
Moonlake Immunotherapeutics target price $14.89, a slight upside of 15.58% compared to current price of $12.57. According to 22 analysts rating.
Investment in Moonlake Immunotherapeutics Shares on INDmoney has dropped by -87.18% over the past 30 days, indicating reduced transactional activity.
Time period: to
Search interest for Moonlake Immunotherapeutics Stock has increased by 22% in the last 30 days, reflecting an upward trend in search activity.
Time period: to
Change:22% versus previous 30 day period
All numbers in Millions USD
All numbers in Millions USD
All numbers in Millions USD
All numbers in Millions USD
Today's Timeline - 29 September
Mon, 07:03 PM
-MoonLake stock down 90% after disappointing Phase 3 VELA trial results, triggering heavy trading activity.
Mon, 07:18 PM
-Analyst downgrades MoonLake to Hold, citing unfavorable Phase 3 results and uncertain market prospects.
Tue, 07:19 AM
-MoonLake stock plummets 89.93% despite significant trial results; after-hours trading shows slight recovery.
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
Price Rise
![]()
In the last 7 days, MLTX stock has moved up by 1.8%
Against Peers
![]()
In the last 1 year, Insmed Incorporated has given 170.5% return, outperforming this stock by 245.4%
Against Peers
![]()
In the last 3 years, Insmed Incorporated has given 954.6% return, outperforming this stock by 898.0%
| Organisation | Moonlake Immunotherapeutics |
| Headquarters | Dorfstrasse 29, Zug, Switzerland, 6300 |
| CEO | Dr. Jorge Santos da Silva Ph.D. |
| E-voting on shares | Click here to vote |
Name | Title |
|---|---|
Ms. Carla Bretes | Director of Investor Relations & External Communications |
Mr. Nicolas Mosimann Ph.D. | General Counsel |
Tino Anthamatten | Vice President of Marketing, Market Access & Pricing |
Luciana Marques | Director of HR, People & Culture |
Ms. Nuala Brennan | Chief Clinical Development Officer |
Mr. Matthias Bodenstedt | Chief Financial Officer |
Mr. Oliver Daltrop Ph.D. | Chief Operations Officer |
Joana Cortez | Senior Director Legal & Compliance |
Dr. Jorge Santos da Silva Ph.D. | Co-Founder, CEO & Director |
Dr. Kristian Reich M.D., Ph.D. | Co-Founder & Chief Scientific Officer |
Moonlake Immunotherapeutics share price today is $12.57 as on . Moonlake Immunotherapeutics share today touched a day high of $13.19 and a low of $12.44.
Moonlake Immunotherapeutics share touched a 52 week high of $62.75 on and a 52 week low of $5.95 on . Moonlake Immunotherapeutics stock price today i.e. is trending at $12.57,which is 79.97% down from its 52 week high and 111.26% up from its 52 week low.
Moonlake Immunotherapeutics market capitalisation is $0.00T as on .
Indian investors can start investing in Moonlake Immunotherapeutics (MLTX) shares with as little as ₹89.642 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹896.42 in Moonlake Immunotherapeutics stock (as per the Rupee-Dollar exchange rate as on ).
Based on Moonlake Immunotherapeutics share’s latest price of $12.57 as on November 21, 2025 at 9:38 pm IST, you will get 0.7955 shares of Moonlake Immunotherapeutics. Learn more about
fractional shares .